Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Фаза 2
Завершено
NCT04205409
| Заболевание | Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | University of Washington |
|---|
| Статус | Завершено |
|---|
| Участники | 20 участн. |
|---|
| Вмешательство | Nivolumab |
|---|
| Дата начала | 5.06.2020 |
|---|
| Дата завершения | 20.09.2024 |
|---|
| Публикация результатов | 3.11.2025 |
|---|
Кратко
This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Best Overall Response Rate (ORR)
Up to 1 year and 8 months · Participants
| Treatment (Nivolumab) | 3 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.